Tirzepatide Research for Heart Failure

The SUMMIT trial evaluated tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Results demonstrated significant improvements in heart failure symptoms and reduced heart failure events. In 731 randomized adults with obesity and HFpEF, cardiovascular death or worsening heart failure occurred in 9.9% on tirzepatide versus 15.3% on placebo (HR 0.62, 95% CI 0.41-0.95). The trial also found a 6.9-point between-group difference in the KCCQ clinical summary score at 52 weeks. The composite was driven mainly by worsening-heart-failure events; cardiovascular deaths were 8 versus 5 and did not show a reduction. These outcomes support benefit in the studied HFpEF-with-obesity population, without establishing a specific disease-modifying mechanism.